Union Health Minister Harsh Vardhan reviewed the process in GTB Hospital in Delhi.Coronavirus India Live Updates: Prime Minister Narendra Modi Sunday called DCGI’s emergency approval for 2 vaccines in India a “decisive turning point” for the country’s vaccine development and expressed gratitude to all frontline workers for their “outstanding” work in fighting against the virus. “It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion,” Modi said on Twitter.
The DCGI in its presser on Sunday gave nod to the “emergency restricted” approval for two vaccine candidates in India, Bharat Biotech’s Covaxin and Oxford-Astrazeneca’s Covishield. The drug controller said that it is paying close attention to the increasing cases of UK’s Covid-19 new strain in the country and was prioritising its threat while conducting clinical trails.
India recorded 18,177 new Covid cases in the 24 hours ending 8 am Sunday, taking the total number of infections to over 1.03 crore. Active cases further dropped to 2.47 lakh, while recoveries continued to rise and stand at over 99.27 lakh. A total of 217 deaths were reported on Saturday, the toll currently stands at over 1.49 lakh. Covid-19 testing on the first two days of the new year have been below one million. Only three states reported more than 1,000 cases on Saturday, but Kerala is still reporting over 5,000 cases. With 5,327 new cases on Saturday, Kerala has so far recorded over 7.71 infections.
A dry run to check the best way to administer Covid-19 vaccine and plug loopholes in logistics and training was held across all states on Saturday. Union Health Minister Harsh Vardhan reviewed the process in GTB Hospital in Delhi and said the government would not compromise on any protocol before approving a vaccine for the novel coronavirus. He appealed to people not to be misguided by rumours regarding the safety and efficacy of vaccines.
Senior Congress leader and Thiruvananthapuram MP Shashi Tharoor criticised the approval for Covaxin and said it was premature and dangerous. "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhanshould please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," Tharoor tweeted.
Delhi Chief Minister Arvind Kejriwal on Sunday said that approval for the emergency use of two "made in India" vaccines will give a positive direction to the country's fight against coronavirus. Congratulating the countrymen, Kejriwal saluted the scientists and doctors for the achievement.
The Drugs Controller General of India (DCGI) on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country. "Congratulations to all the countrymen. Approval by DCGI to emergency use of two made in India vaccines will give a positive direction to the country's fight against corona. Salute to the scientists and doctors whose hard work helped us reach here," Kejriwal tweeted in Hindi.
The World Health Organisation on Sunday welcomed India's decision giving emergency use authorisation to COVID-19 vaccines, saying it will help "intensify" and "strengthen" its fight against the ongoing pandemic. India's drugs regulator has approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country. It paves the way for the roll out of at least two vaccines in the country in the coming days.
"WHO welcomes the first emergency use authorization given to COVID-19 vaccine in the WHO South-East Asia Region. This decision taken today by India will help intensify and strengthen the fight against COVID-19 pandemic in the Region," said Dr Poonam Khetrapal Singh, the regional director, WHO South-East Asia Region.
According to Khetrapal, the use of vaccine in "prioritised population" as well as implementation of other public health measures will be important in reducing the impact of the pandemic.
"The use of vaccine in prioritised populations, along with continued implementation of other public health measures and community participation will be important in reducing the impact of COVID-19," she added. (PTI)
Samajwadi Party president Akhilesh Yadav on Sunday said the COVID-19 vaccination programme is a "sensitive process", and the government should not to treat it as "cosmetic" event as it is matter of lives of people. Yadav had on Saturday termed the anti-Covid vaccine to be rolled out in the country as a "vaccine of the BJP" and said he would not take the shot, prompting a sharp reaction not only from the ruling party but also from NC vice-president Omar Abdullah.
The fresh remarks by the SP chief come on a day when India's drugs regulator approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive. (PTI)
A South Korean health official said on Sunday that a third wave of the novel coronavirus is being contained, as it reported the lowest number of new infections in nearly four weeks with the help of tougher restrictions during the New Year holiday season.
New cases for Saturday numbered 657, much lower than 824 the day before, but bringing the country's total cases to 63,244 with 962 deaths, according to the Korea Disease Control and Prevention Agency (KDCA).
"The latest third wave of coronavirus spread is being contained as a result of expanded COVID-19 testing (recently) and strengthened distancing measures," Sohn Young-rae, a senior health official, told a briefing.
He said the worst for the country seems to be passing, though added it is premature to say the situation has definitely shifted to a decline, given the decreased testing during the New Year holiday and weekends.
Bahujan Samaj Party supremo Mayawati on Sunday congratulated the scientists associated with the coronavirus vaccine and urged the Centre to make it available for the poor free of cost.
In a tweet in Hindi, Mayawati said, "The 'swadeshi' anti-Covid vaccine is welcome and congratulations to the scientists. A request to the Central government is that along with all the health workers, if the extremely poor people get the vaccine free of cost, then it will be appropriate."
Thailand's government held off from ordering new nationwide business shutdowns on Sunday amid a new wave of coronavirus cases but empowered some provincial governors to set their own restrictions and pleaded with the public not to travel. Thailand, which had largely controlled the virus by mid-2020, saw a second wave of outbreaks beginning in December. On Sunday, it confirmed 315 new coronavirus cases, the majority of which are from local transmission, bringing its total to 7,694 cases and 64 deaths since its first case last January. The country also reported its first known case of a more contagious variant of the coronavirus called B.1.1.7 on Sunday, Yong Poovorawan, a senior virologist from Chulalongkorn University in Bangkok, said in a post on his official Facebook page.
Senior Congress leader Anand Sharma on Sunday raised concerns over India's drugs regulator granting permission for restricted use of Bharat Biotech's COVID-19 vaccine and asked the government to explain why mandatory protocols and verification of data has been dispensed with. India's drugs regulator DCGI on Sunday approved Oxford's COVID-19 vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use. Sharma, who heads the Parliamentary panel on Home Affairs which dealt with the issue at length, said the issue of granting authorisation to the vaccine use needs to be taken carefully as no country has dispensed with the mandatory phase 3 trials and verification of data. As per submissions made before the expert panel, phase 3 trials have not been completed and therefore, the data on safety and efficacy has not been reviewed, which is a mandatory requirement, he said.
Soon after the DCGI nod, Adar Poonawalla, Serum Institute of India (SII) CEO, tweeted, “Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India’s first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks.”
The Drugs Controller General of India in its presser stated that the interim data suggested that the vaccines are safe to use. A few pointers from today's presser.
After the Drug Controller General of India (DCGI) on Sunday approved the emergency use of both Oxford-AstraZeneca’s Covishield and Bharat Biotech’s Covaxin for immunisation against Covid-19 in India, Prime Minister Narendra Modi tweeted that every Indian is proud that both the shots are “made in India.” Stating that the DGCI approval shows the “eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat,” PM Modi tweeted, “It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion.”
Prime Minister Narendra Modi called DCGI’s emergency approval for 2 vaccines in India a “decisive turning point” in the country’s fight against the virus and expressed gratitude for all frontline workers in “adverse circumstances.”It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion,” Modi said on Twitter.
The DCGI in its presser on Sunday gave nod to the “emergency restricted” approval for two vaccine candidates in India, Bharat Biotech’s Covaxin and Oxford-Astrazeneca’s Covishield. The drug controller said that it is paying close attention to the increasing cases of UK’s Covid-19 new strain in the country and was prioritising its threat while conducting clinical trails.
The DCGI on Sunday said that Bharat Biotech's ongoing clinical trial will continue across the nation and the threat of the UK's new strain is being prioritised while doing so. The firm is set to conduct its phase 3 trials in another 26,000 patients across the country.
The Drug Controller General of India (DCGI) is expected to make some big announcement on Covid-19 vaccination in India during a press conference scheduled on Sunday, 11 am. Speculations are on that the announcement by the drug controller watchdog may include approval of the emergency use of two vaccines –– Oxford-AstraZeneca Covishield and Bharat Biotech’s Covaxin–– after the expert panel of Central Drugs Standard Control Organisation (CDSCO) recommended them for emergency use.
On January 1, Covishield was recommended for emergency use whereas Covaxin was recommended for restricted use on January 2. Now. a final approval by DCGI on the use of both vaccines is awaited.
A diminished sense of smell, called anosmia, has emerged as one of the telltale symptoms of COVID-19. It is the first symptom for some patients, and sometimes the only one. Often accompanied by an inability to taste, anosmia occurs abruptly and dramatically in these patients, almost as if a switch had been flipped.
Most regain their senses of smell and taste after they recover, usually within weeks. But in a minority of patients, the loss persists, and doctors cannot say when or if the senses will return.
Scientists know little about how the virus causes persistent anosmia or how to cure it. But cases are piling up as the coronavirus sweeps across the world, and some experts fear that the pandemic may leave huge numbers of people with a permanent loss of smell and taste.(Read more here)
India recorded 18,177 new Covid cases in the 24 hours ending 8 am Sunday, taking the total number of infections to over 1.03 crore. Active cases further dropped to 2.47 lakh, while recoveries continued to rise and stand at over 99.27 lakh. A total of 217 deaths were reported on Saturday, the toll currently stands at over 1.49 lakh.
An expert panel under India’s top drug regulator on Saturday recommended restricted emergency approval for Covaxin, Bharat Biotech’s Covid-19 vaccine candidate that is currently under testing in the country.
The expert panel has now recommended restricted clearance for two vaccine candidates in as many days — on Friday, it recommended similar approval for Covishield, the variant of the Oxford-AstraZeneca vaccine that is being manufactured under licence in India by Pune-based Serum Institute of India.The recommendations in favour of Covishield and Covaxin pave the way for Drug Controller General of India (DCGI) Dr V G Somani to clear the two candidates for use in the country’s imminent mass vaccination programme.
The DCGI is scheduled to make a statement to the media on the Covid-19 vaccine at 11 am on Sunday.(With Prabha Raghavan)